Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Radar™  A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata Notes Completion of Acquisition by NeoGenomics

Research Triangle Park, NC, USA and Cambridge, UK, 18 June 2021 -- Inivata, a leader in liquid biopsy, today announces that ... Read More

Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Kirsten McLay, Giovanni Marsico, Christoph Walz, Olivier ... Read More

2021 CB & CDx Digital Event

2021 CB & CDx Digital Event

Event expiration date display - 29 - 30 SEPT 2021

Location: Online Event Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

In case you missed it, #TeamInivata and our collaborators presented at @EACRnews last month, showcasing preliminary results of the #LiquidBiopsy for miNimal rESidual diSease detection in head & neck squamous cell carcinoma (LIONESS) study. More here: http://bit.ly/3wF4SPk

By providing key insights to clinicians and #healthcare teams, our personalized, multi-#tumor assay, #RaDaR™, can help empower & inform their decision-making around whether adjuvant therapy is needed for an individual patient. #MRD More here: https://www.inivata.com/radar-applications-of-radar/

Our Head of Science and Innovation, Tim Forshew has teamed up with Medical Advisor, Stefan Scherer to provide a #webinar on the ‘Practical Applications of #ctDNA Testing for #MRD & Recurrence detection in the era of precision #oncology’. Watch on demand: https://bit.ly/36A3F0d

LinkedIn tracking code Twitter tracking code